Feedback PLC - Half-year Report
Feedback plc
Half Year Results to
Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the clinical infrastructure specialists, announces its unaudited results for the six months to
Operational Highlights and Developments
· Bleepa's proven, highly scalable model strongly positioned to fulfil NHS productivity requirements
· A national business case for Bleepa was submitted as part of the Spending Review in the Spring - outcome pending
· Integrations into eRS, PDS and GP Connect were completed (and implemented post period) - positioning Feedback for national scale
· NSS pathway went live on Bleepa in Sussex ICS, second at scale pathway-proving Bleepa can also run cancer pathways
· Strategic partnerships in late stage discussion ahead of at scale roll out including consulting firms for implementation, cloud providers and technology partners with supporting propositions
· Bleepa was selected to run the
Financial Highlights
· Revenue remains stable at
· EBITDA(1) loss increased to
· Cash as at
· The Company remains in a stable financial position and has been laying the groundwork ready to scale in 2026/27
Post period Highlights
· Continued engagement with the NHS at all levels (national, ICB and trust)
· Increasing dialogue with larger partners to the NHS around deploying Bleepa in their offerings
· Over the period, all of our existing clients have renewed their contracts and Queen Victoria Hospital NHS Foundation Trust ("QVH") in particular is focussed on building out more pathways
· New CFO appointed on 10th
Investor Presentation: 16.00 today
Management will be providing a presentation and hosting an investor Q&A session on the Company's results and outlook at 16.00 today. Investors can sign up for free and register to meet FDBK via the following link: https://www.investormeetcompany.com/feedback-plc/register-investor
Questions can be submitted pre-event and at any time during the live presentation via the Investor Meet Company Platform.
Dr
"The NHS 10 Year Plan and its stated direction of travel are closely aligned with the solutions provided by Feedback Medical. Funding committed through the NHS Spending Review is expected to flow to frontline services for the upcoming 2026/27 NHS year. This combined with increasing recognition of the role of technology in healthcare and the need for material productivity improvements across the system has the potential to support a new phase of commercial progress for Feedback."
Note (1): "Adjusted EBITDA Loss" is a non-IFRS metric being EBITDA less share-based payment charges.
Enquiries:
|
Feedback plc |
+44 (0) 20 3997 7634 |
|
|
|
|
Panmure Liberum Limited (NOMAD and Broker) |
+44 (0)20 7886 2500 |
|
|
|
|
Walbrook PR Ltd; |
Tel: 020 7933 8780 or feedbackplc@walbrookpr.com |
|
|
07748 325 236 or 07867 984 082 |
About Feedback plc
Feedback plc is the strategic partner to unlock productivity in health and care through digital connectivity and asynchronous collaboration. With proven expertise in system integration, we enable teams to work flexibly, share information securely, and deliver care more efficiently.
Bleepa® is an award-winning collaboration platform that improves the quality and productivity of patient pathways enabling health and care organisations to hit targets with their existing clinical workforce. We achieve this by connecting digital infrastructure across systems, enabling asynchronous working, reducing geographic barriers and removing unnecessary appointments.
Bleepa supports the shift from analogue to digital and from hospital to community-based care, by uniting essential data and teams to enhance clinical decision making and enable better coordinated care.
The Company has a number of growth opportunities domestically and internationally across a range of public and private healthcare markets including the NHS. Our highly scalable software-as-a-service (SaaS) based model is expected to provide increasing levels of revenue visibility as the Company grows its customer base.
Feedback plc
Chairman and Chief Executive Officer Statement
As expected, external factors continued to impact the Company's ability to deliver growth in sales and revenue during the period, however, a lot of work has been achieved in the background to position the Company for near term growth, and whilst local contracts were difficult to secure during the period, the Company has set its sights on larger national and regional contracts that recognise the productivity benefits of cross-provider working and new care models that Bleepa enables.
Following a multiyear engagement strategy and growing evidence from the
Strongly positioned to deliver at multiple levels
Feedback's growing toolkit of capabilities enables it to address the needs of a wide range of customer pathways and end solutions, highlighting multiple use cases across the healthcare system, including reducing outpatient journey times, as a single point of access, and neighbourhood health. The result is a strong value proposition into ICS and Acute Provider Collaboratives that are looking to drive productivity through new operating models, in addition to the national opportunity outlined above.
Positioning Bleepa during the Period focused further on refining its offering across three distinct routes to market: (i) national programmes; (ii) regional and Integrated Care Board (ICB) deployments; and (iii) individual provider organisations, with interest across all three routes increasing during the Period. At QVH, expanded usage across additional clinical pathways including Non Site Specific Symptoms (NSS), enabled the Company to more clearly demonstrate the impact of its platform to prospective customers, with two further pathways scheduled to go live in the near term. Importantly, the lifetime value of individual contracts, which continue to be successfully renewed highlights the strength of the Company's proposition, underpinning confidence in its sustainable business model.
Acting as the technology provider for neighbourhood health simulations in London and Manchester in conjunction with the leading enterprise management consultancy firm PPL and Optum, the Company was able to further prove the benefits of its solutions around neighbourhood health delivery, aligned with the 10 Year Plan for the NHS.
These simulations highlighted the importance of shared digital infrastructure in enabling system-wide change and demonstrated potential benefits, including a 25% reduction in outpatient appointments and a 14% decrease in unplanned admissions. This work was supported by the Company's own white paper on neighbourhood health, with the Company also providing evidence to the Health All-Party Parliamentary Group inquiry into neighbourhood health.
Following continued investment in product development, a new version of Bleepa will be rolled out across customer sites in the coming months. This incorporates significant improvements to the user experience and has received positive initial responses during demonstrations. In addition, this upgrade will include configurable forms to automate communications. The Company has also maintained its high standards in regulatory compliance and information security. With the recent go-live of the NHS electronic referral service (eRS) integration, Bleepa is now natively integrated into a core NHS system, further strengthening assurance around data management and cyber security.
Given the significant domestic opportunity the Company is focusing on the
Supportive backdrop underpinning growth potential
With the NHS funding envelope anticipated to open in April and increasing recognition of Bleepa's value proposition from target customers, management believes that Feedback plc and Bleepa are both well positioned to benefit from upcoming growth opportunities in the NHS and will be central to its digital transformation.
The current emphasis on productivity improvement within the NHS is particularly supportive of Bleepa's solutions. Emerging funding streams appear less focused on large-scale Electronic
Furthermore, the Government published its 10 Year Plan in
Against this backdrop, the Spending Review, which is expected to flow to frontline services from 2026/27, included a commitment to additional technology investment of up to
Combined with an ongoing policy focus on reducing elective care waiting lists and improving public sector productivity, this provides improved medium-term visibility on NHS investment priorities. With clearer leadership and commissioning structures now emerging at local, regional and national levels, the operating environment is becoming more conducive to procurement activity and programme delivery. Together with increasing recognition of the role of technology in healthcare and the need for material productivity improvements across the system, there is significant potential for a new phase of commercial progress at Feedback.
Financial Review
Revenue for the Period decreased 8% to
Sales, a non IFRS measure representing the total customer contract value signed in the period, decreased 47% to
Sales are recognised as revenue monthly across the life of a customer contract (typically 12 months), with any amount not recognised as revenue in the current financial year remaining on the balance sheet as contractual liabilities to be recognised as revenue when the service is delivered.
Gross margin decreased from 89% in H1 2025 to 81% in H1 2026 as we introduced proactive client platform monitoring and rolled out new patient pathways for QVH.
Operating expenses decreased 7% to
EBITDA loss, excluding depreciation and amortisation charges of
The Company capitalised a further
The Company's cash position as at
Outlook
With the injection of 3-year capital funding into the NHS post the spending review, and the move to strategic commissioning by ICBs it is likely that larger regional or even national contracts will become available at the start of the next NHS financial year (from
|
Feedback plc |
|
|
|
|
|
|||||
|
Consolidated Statement of Comprehensive Income |
|
|||||||||
|
For the six months ending |
|
|||||||||
|
|
|
|
|
|
|
|
||||
|
|
Note |
6 months ending (Unaudited) £'000 |
6 months ending (Unaudited) £'000 |
12 months ending 31 May 2025 (Audited) £'000 |
||||||
|
|
|
|
|
|
||||||
|
Revenue |
4 |
413 |
449 |
886 |
||||||
|
Cost of sales |
|
(76) |
(49) |
(107) |
||||||
|
|
|
|
|
|
||||||
|
Gross profit |
|
337 |
400 |
779 |
||||||
|
Other income |
|
94 |
- |
160 |
||||||
|
Other operating expenses |
|
(2,218) |
(2,389) |
(5,149) |
||||||
|
|
|
|
|
|
||||||
|
Operating loss |
|
(1,787) |
(1,989) |
(4,211) |
||||||
|
Impairment of intangible assets |
|
- |
- |
(3,192) |
||||||
|
Net finance income |
|
64 |
38 |
118 |
||||||
|
|
|
|
|
|
||||||
|
Loss before taxation |
|
(1,723) |
(1,951) |
(7,284) |
||||||
|
Tax (charge)/credit |
|
(19) |
73 |
(32) |
||||||
|
|
|
|
|
|
||||||
|
|
|
|
|
|
||||||
|
Loss after tax attributable to the equity shareholders of the Company |
|
(1,742) |
(1,878) |
(7,317) |
||||||
|
|
|
|
|
|
||||||
|
Translation difference on overseas operation |
|
7 |
(2) |
11 |
||||||
|
Total comprehensive loss for the year |
|
(1,735) |
(1,880) |
(7,307) |
||||||
|
|
|
|
|
|
||||||
|
Loss per share (pence)* |
|
|
|
|
||||||
|
Basic and diluted |
2 |
(3.98) |
(4.29) |
(16.70) |
||||||
* Loss per share has been calculated based on the weighted average number of shares in issue during each period
|
Feedback plc |
|
|
|
|
|
|
||||||||
|
Condensed Consolidated Statement of Changes in Equity For the six months ending |
|
|
||||||||||||
|
|
|
|
|
|
|
|
|
|||||||
|
|
Share Capital |
Share Premium |
Capital Reserve |
Retained Earnings |
Translation Reserve |
Share option Reserve |
Total |
|||||||
|
|
£'000 |
£'000 |
£'000 |
£'000 |
£'000 |
£'000 |
£'000 |
|||||||
|
|
|
|
|
|
|
|
|
|||||||
|
At (Audited) |
6,972 |
20,655 |
300 |
(22,383) |
(202) |
822 |
6,164 |
|||||||
|
|
|
|
|
|
|
|
|
|||||||
|
Loss for the year and Total comprehensive loss for the year |
- |
- |
- |
(1,742) |
7 |
- |
(1,735) |
|||||||
|
|
|
|
|
|
|
|
|
|||||||
|
Share-based payments |
- |
- |
- |
- |
- |
32 |
32 |
|||||||
|
Total transactions with owners |
- |
- |
- |
- |
- |
32 |
32 |
|||||||
|
|
|
|
|
|
|
|
|
|||||||
|
At (Unaudited) |
6,972 |
20,655 |
300 |
(24,125) |
(195) |
854 |
4,461 |
|||||||
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
|
|||||||
|
|
Share Capital |
Share Premium |
Capital Reserve |
Retained Earnings |
Translation Reserve |
Share option Reserve |
Total |
|||||||
|
|
£'000 |
£'000 |
£'000 |
£'000 |
£'000 |
£'000 |
£'000 |
|||||||
|
|
|
|
|
|
|
|
|
|||||||
|
At (Audited) |
6,667 |
15,350 |
300 |
(15,065) |
(212) |
605 |
7,645 |
|||||||
|
|
|
|
|
|
|
|
|
|||||||
|
Loss for the year and Total comprehensive loss for the year |
- |
- |
- |
(1,878) |
(2) |
- |
(1,880) |
|||||||
|
|
|
|
|
|
|
|
|
|||||||
|
New shares issued |
305 |
5,791 |
- |
- |
- |
- |
6,096 |
|||||||
|
Costs of new shares issued |
- |
(484) |
- |
- |
- |
- |
(484) |
|||||||
|
Share-based payments |
- |
- |
- |
- |
- |
38 |
38 |
|||||||
|
Total transactions with owners |
305 |
5,307 |
- |
- |
- |
38 |
5,650 |
|||||||
|
|
|
|
|
|
|
|
|
|||||||
|
At (Unaudited) |
6,972 |
20,657 |
300 |
(16,943) |
(214) |
643 |
11,415 |
|||||||
|
Condensed Consolidated Statement of Financial Position For the six months ending 30 |
||||
|
|
|
(Unaudited) |
(Unaudited) |
31 May 2025 (Audited) |
|
|
Note |
£'000 |
£'000 |
£'000 |
|
Assets |
|
|
|
|
|
Non-current assets |
|
|
|
|
|
Property, plant and equipment |
|
9 |
8 |
12 |
|
Intangible assets |
3 |
717 |
3,956 |
564 |
|
|
|
726 |
3,964 |
576 |
|
|
|
|
|
|
|
Current assets |
|
|
|
|
|
Trade and other receivables |
|
106 |
100 |
99 |
|
Called up share capital not yet paid |
|
- |
499 |
- |
|
Corporation tax receivable |
|
206 |
373 |
129 |
|
Cash and cash equivalents |
|
3,823 |
7,259 |
5,950 |
|
|
|
4,135 |
8,231 |
6,178 |
|
|
|
|
|
|
|
Total assets |
|
4,861 |
12,195 |
6,754 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity |
|
|
|
|
|
Capital and reserves attributable to the Company's equity shareholders |
|
|
|
|
|
Called up share capital |
|
6,972 |
6,972 |
6,972 |
|
Share premium account |
|
20,655 |
20,657 |
20,655 |
|
Capital reserve |
|
300 |
300 |
300 |
|
Translation reserve |
|
(195) |
(214) |
(202) |
|
Share option expense reserve |
|
854 |
643 |
822 |
|
Retained earnings |
|
(24,125) |
(16,943) |
(22,383) |
|
Total equity |
|
4,461 |
11,415 |
6,164 |
|
|
|
|
|
|
|
Liabilities |
|
|
|
|
|
Current liabilities |
|
|
|
|
|
Trade and other payables |
|
400 |
780 |
589 |
|
|
|
400 |
780 |
589 |
|
|
|
|
|
|
|
Total liabilities |
|
400 |
780 |
589 |
|
|
|
|
|
- |
|
Total equity and liabilities |
|
4,861 |
12,195 |
6,754 |
|
Feedback plc |
|||
|
Consolidated Statement of Cash Flows For the six months ending |
|||
|
|
6 months ending 30 November 2025 (Unaudited) £'000 |
6 months ending 30 November 2024 (Unaudited) £'000 |
12 months ending 31 May 2025 (Audited) £'000 |
|
|
|
|
|
|
Cash flows from operating activities |
|
|
|
|
Loss before tax |
(1,723) |
(1,951) |
(7,285) |
|
Adjustments for: |
|
|
|
|
|
|
|
|
|
Net finance income |
(64) |
(38) |
(118) |
|
Other Income - R&D tax credit |
(94) |
- |
(160) |
|
Depreciation and amortisation |
180 |
554 |
1,147 |
|
Impairment of intangible assets |
- |
- |
3,192 |
|
Share based payment expense |
32 |
38 |
217 |
|
Decrease/(increase) in trade receivables |
(0) |
0 |
(1) |
|
Decrease/(increase) in other receivables |
(8) |
(18) |
(16) |
|
Increase / (decrease) in trade payables |
10 |
25 |
(66) |
|
Increase / (decrease) in other payables |
(200) |
60 |
(39) |
|
Corporation tax |
(2) |
(1) |
297 |
|
Translation difference on overseas operation |
7 |
(2) |
11 |
|
Total adjustments |
(139) |
618 |
4,464 |
|
|
|
|
|
|
Net cash used in operating activities |
(1,862) |
(1,332) |
(2,821) |
|
|
|
|
|
|
Cash flows from investing activities |
|
|
|
|
Purchase of tangible fixed assets |
(3) |
(1) |
(11) |
|
Purchase of intangible assets |
(326) |
(436) |
(823) |
|
Net finance income received |
64 |
38 |
118 |
|
|
|
|
|
|
Net cash used in investing activities |
(265) |
(399) |
(716) |
|
|
|
|
|
|
Cash flows from financing activities |
|
|
|
|
Net proceeds of share issue |
- |
5,113 |
5,609 |
|
|
|
|
|
|
Net cash generated from financing activities |
- |
5,113 |
5,609 |
|
|
|
|
|
|
Net increase/(decrease) in cash and cash equivalents |
(2,127) |
3,381 |
2,072
|
|
Cash and cash equivalents at beginning of period |
5,950 |
3,878 |
3,878 |
|
|
|
|
|
|
Cash and cash equivalents at end of period |
3,823 |
7,259 |
5,950 |
Notes to the Interim results for the six months to
1. Basis of preparation
Feedback plc is a public limited company listed on the on the Alternative Investment Market ("AIM") of the London Stock Exchange (AIM: FDBK) and is incorporated and domiciled in the
The interim condensed financial statements of Feedback plc have been prepared in accordance with International Accounting Standard 34 Interim Financial Reporting as adopted in the
The interim condensed consolidated financial statements do not constitute statutory accounts within the meaning of Section 434 of the Companies Act 2006. The statutory accounts for the 12 months ending
The published financial statements for the year ended
There are no material events to report after the end of the reporting period.
This interim report was approved by the Board of Directors on
2. Loss per share
Basic loss per share is calculated by reference to the loss on ordinary activities after taxation and on the weighted average number of ordinary shares in issue.
|
|
6 months ending 30 November 2025 (Unaudited) £'000 |
*6 months ending 30 November 2024 (Unaudited) £'000 |
*12 months ending 31 May 2025 (Audited) £'000 |
|
|
|
|
|
|
Net loss attributable to ordinary equity holders |
(1,742) |
(1,878) |
(7,317) |
|
|
|
|
|
|
Weighted average number of ordinary shares for basic earnings per share |
43,814,779 |
13,667,775 |
28,699,980 |
|
Effect of dilution: |
|
|
|
|
Share Options |
- |
- |
- |
|
Warrants |
- |
- |
- |
|
Weighted average number of ordinary shares adjusted for the effect of dilution |
43,814,779 |
13,667,775 |
28,699,980 |
|
|
|
|
|
|
Loss per share (pence)* |
|
|
|
|
Basic |
(3.98) |
(13.74) |
(25.50) |
|
Diluted |
(3.98) |
(13.74) |
(25.50) |
*Loss per share has been calculated based on the weighted average number of shares in issue for each period.
3. Intangible assets
|
|
Software development |
Intellectual Property |
Total |
|
|
£'000 |
£'000 |
£'000 |
|
Cost |
|
|
|
|
|
|
|
|
|
At |
6,924 |
205 |
7,129 |
|
Additions |
436 |
- |
436 |
|
At |
7,360 |
205 |
7,565 |
|
Additions |
387 |
- |
387 |
|
At |
7,747 |
205 |
7,952 |
|
Additions |
327 |
- |
327 |
|
At |
8,074 |
205 |
8,279 |
|
|
|
|
|
|
Amortisation |
|
|
|
|
|
|
|
|
|
At |
2,885 |
176 |
3,061 |
|
Charge for the year |
542 |
6 |
548 |
|
At |
3,427 |
182 |
3,609 |
|
Charge for the year |
581 |
6 |
587 |
|
Impairment charge for the year |
3,175 |
17 |
3,192 |
|
At |
7,183 |
205 |
7,388 |
|
Charge for year |
174 |
- |
174 |
|
At |
7,357 |
205 |
7,562 |
|
|
|
|
|
|
Net Book Value
|
|
|
|
|
At |
717 |
- |
717 |
|
|
|
|
|
|
At |
564 |
- |
564 |
|
|
|
|
|
|
At |
3,933 |
23 |
3,956 |
4. Segmental reporting
The Directors have determined that the operating segments based on the management reports which are used to make strategic decisions are medical imaging and head office. The trading activities of the Company solely relate to Medical Imaging and the Head Office covers the costs of running the parent company, Feedback Plc.
|
Six months ending |
|
Medical Imaging |
Feedback Medical Imaging India |
Head Office |
Total |
|
|
|
£ |
£ |
£ |
£ |
|
Revenue |
|
|
|
|
|
|
External |
|
410 |
3 |
- |
413 |
|
Expenditure |
|
|
|
|
|
|
Total (excluding depreciation and amortisation) |
(1,375) |
(68) |
(607) |
(2,050) |
|
|
Depreciation and amortisation |
(179) |
(0) |
- |
(180) |
|
|
Other Income - tax credit |
94 |
- |
- |
94 |
|
|
Loss before tax |
|
(1,050) |
(65) |
(607) |
(1,723) |
|
|
|
|
|
|
|
|
Balance sheet |
|
|
|
|
|
|
Total assets |
|
1,049 |
17 |
3,795 |
4,861 |
|
Total liabilities |
|
(323) |
(1) |
(76) |
(400) |
|
|
|
726 |
16 |
3,719 |
4,461 |
|
|
|
|
|
|
|
|
Capital expenditure |
(329) |
- |
- |
(329) |
|
|
|
|
|
|
|
|
The revenues from external customers in the six months ending
|
||||
|
Six months ending
|
Medical Imaging |
Head Office |
Total |
|
|
|
|
£'000 |
£'000 |
£'000 |
|
Revenue |
|
|
|
|
|
External |
|
449 |
- |
449 |
|
Expenditure |
|
|
|
- |
|
Total (excluding depreciation and amortisation) |
|
(1,299) |
(547) |
(1,846) |
|
Depreciation and amortisation |
|
(554) |
- |
(554) |
|
Loss before tax |
|
(1,404) |
(547) |
(1,951) |
|
Tax credit |
|
73 |
- |
73 |
|
|
||||
|
Balance sheet |
||||
|
Total assets |
|
5,044 |
7,151 |
12,195 |
|
Total liabilities |
|
(642) |
(139) |
(780) |
|
|
|
4,402 |
7,013 |
11,415 |
|
|
|
|
|
|
|
Capital expenditure (all located in the |
|
(436) |
- |
(436) |
|
|
|
|
|
|
Reported segments' assets are reconciled to total assets as follows:
|
|
External revenue by |
Non-current assets by |
Total liabilities by |
|||
|
|
location of customer |
location of assets |
location of assets |
|||
|
|
6 months ending 30 November 2025 (Unaudited) |
6 months ending 30 November 2024 (Unaudited) |
6 months ending 30 November 2025 (Unaudited) |
6 months ending 30 November 2024 (Unaudited) |
6 months ending 30 November 2025 (Unaudited) |
6 months ending 30 November 2024 (Unaudited) |
|
|
£'000 |
£'000 |
£'000 |
£'000 |
£'000 |
£'000 |
|
|
|
|
|
|
|
|
|
|
382 |
420 |
724 |
3,964 |
398 |
780 |
|
|
- |
- |
- |
- |
- |
- |
|
Rest of world |
31 |
29 |
1 |
- |
2 |
- |
|
Total |
413 |
449 |
725 |
3,964 |
400 |
780 |
5. Availability of this report
A copy of this announcement is available from the Company's website, being: https://feedbackmedical.com/resources/resource-hub/.
To receive a hard copy of the interim report, please contact Walbrook Ltd on 020 7933 8780 or feedbackplc@walbrookpr.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE